<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102409</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-DED-025</org_study_id>
    <nct_id>NCT05102409</nct_id>
  </id_info>
  <brief_title>An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease</brief_title>
  <official_title>An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects With Dry Eye Disease in a Dry Eye Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and&#xD;
      Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects with Dry&#xD;
      Eye Disease in a Dry Eye Chamber&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event (AE) Query</measure>
    <time_frame>Through trial completion, approximately four weeks</time_frame>
    <description>Collection of AEs during the trial</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xiidra® (5% lifitegrast ophthalmic solution)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reproxalap Ophthalmic Solution (0.25%)</intervention_name>
    <description>Reproxalap Ophthalmic Solution (0.25%) dosed once</description>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiidra® (5% lifitegrast ophthalmic solution)</intervention_name>
    <description>Xiidra® (5% lifitegrast ophthalmic solution) dosed once</description>
    <arm_group_label>Xiidra® (5% lifitegrast ophthalmic solution)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eighteen (18) to70 years of age at the time of screening (either gender and any race).&#xD;
&#xD;
          2. Ability to provide written informed consent.&#xD;
&#xD;
          3. Reported history of dry eye for at least 6 months prior to Visit 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal) or active&#xD;
             ocular inflammation at Visit 1.&#xD;
&#xD;
          2. Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during&#xD;
             the trial.&#xD;
&#xD;
          3. A condition that the investigator feels may put the subject at significant risk may&#xD;
             confound the study results or may interfere significantly with the subject's&#xD;
             participation in the trial.&#xD;
&#xD;
          4. Inability or unwillingness to follow instructions, including participation in all&#xD;
             study assessments/procedures and visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bill Cavanagh</last_name>
    <phone>781-257-3063</phone>
    <email>bcavanagh@aldeyra.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliantha Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Couroux, MD</last_name>
      <phone>905-282-1808</phone>
      <email>pcouroux@cliantha.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Lifitegrast</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

